. "26" . "Polyhedron" . "The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O" . "RIV/00216224:14310/07:00033220!RIV10-MSM-14310___" . "Z(MSM0021622415)" . "GB - Spojen\u00E9 kr\u00E1lovstv\u00ED Velk\u00E9 Brit\u00E1nie a Severn\u00EDho Irska" . "2"^^ . . . . . "Popa, I." . . "RIV/00216224:14310/07:00033220" . "18" . . . "A series of Pt(IV) complexes with cytokinins or CDK-inhibitors derived from 6-benzylaminopurine (Bap) of the composition [Pt-IV(LH+)Cl-5] (1-14), where LH+ stands for protonated form of the Bap derivative (1-12), Boh = 6-(benzylamino)-2-[(3-hydroxypropyl)amino]-9-isopropylpurine, bohemine (13) and Ros = 6-(benzylamino)-2-[(1-hydroxymethylpropyl)amino]-9-isopropylpurine, roscovitine (14), have been prepared. They have been fully characterized by microanalysis, conductivity, FT-IR, H-1, C-13, N-15 and Pt-195 NMR and ES+ mass spectroscopy. All of the compounds have been tested in vitro for their cytotoxicity against four human cancer cell lines: malignant melanoma (G361), osteogenic sarcoma (HOS), chronic myelogenous erythroleukemia (K562) and breast adenocarcinoma (MCF7). The molecular structures of two ionic pair compounds (BohH(2)(2+))[PtCl6] center dot H2O (15) and (RosH(2)(2+))(2)[PtCl6]Cl-2 center dot 4H(2)O (16) have been determined by a single crystal X-ray analysis."@en . . . "5"^^ . . . "[23BB2884BC7D]" . "Herchel, R." . "The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O" . . . . "Tr\u00E1vn\u00ED\u010Dek, Z." . "Platinum(IV) complexes; Cytotoxicity; 6-Benzylaminopurine; Cytokinins; Bohemine; Roscovitine"@en . . "A series of Pt(IV) complexes with cytokinins or CDK-inhibitors derived from 6-benzylaminopurine (Bap) of the composition [Pt-IV(LH+)Cl-5] (1-14), where LH+ stands for protonated form of the Bap derivative (1-12), Boh = 6-(benzylamino)-2-[(3-hydroxypropyl)amino]-9-isopropylpurine, bohemine (13) and Ros = 6-(benzylamino)-2-[(1-hydroxymethylpropyl)amino]-9-isopropylpurine, roscovitine (14), have been prepared. They have been fully characterized by microanalysis, conductivity, FT-IR, H-1, C-13, N-15 and Pt-195 NMR and ES+ mass spectroscopy. All of the compounds have been tested in vitro for their cytotoxicity against four human cancer cell lines: malignant melanoma (G361), osteogenic sarcoma (HOS), chronic myelogenous erythroleukemia (K562) and breast adenocarcinoma (MCF7). The molecular structures of two ionic pair compounds (BohH(2)(2+))[PtCl6] center dot H2O (15) and (RosH(2)(2+))(2)[PtCl6]Cl-2 center dot 4H(2)O (16) have been determined by a single crystal X-ray analysis." . . "The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O"@en . "14310" . "The first platinum(IV) complexes involving aromatic cytokinins or cyclin-dependent kinase inhibitors derived from 6-benzylaminopurine: X-ray structures of (BohH(2)(2+))[PtCl6].H2O and (RosH(2)(2+))(2)[PtCl6]Cl-2.4H(2)O"@en . "422100" . "Marek, Jarom\u00EDr" . "\u010Cajan, Michal" . . "0277-5387" . "12"^^ . .